IGF1 and prostate neoplasm: Although recent advancements in next-generation sequencing technology have improved our understanding of the biology of prostate tumors [12], emphasizing the genetic basis of clinical variability of the disease, the impact of the molecular heterogeneity of PCa on the IGF axis has never been considered at clinical level.